Who are ARQ 197 plus erlotinib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arq-197-plus-erlotinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ARQ 197 plus erlotinib — Competitive Intelligence Brief

ARQ 197 plus erlotinib (ARQ 197 plus erlotinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: c-MET inhibitor, EGFR inhibitor. Area: Oncology.

phase 2 c-MET inhibitor, EGFR inhibitor c-MET, EGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ARQ 197 plus erlotinib (ARQ 197 plus erlotinib) — ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA). ARQ 197 is a small molecule inhibitor of c-MET, and when combined with erlotinib, targets the EGFR and c-MET pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARQ 197 plus erlotinib TARGET	ARQ 197 plus erlotinib	ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)	phase 2	c-MET inhibitor, EGFR inhibitor	c-MET, EGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (c-MET inhibitor, EGFR inhibitor class)

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARQ 197 plus erlotinib — Competitive Intelligence Brief. https://druglandscape.com/ci/arq-197-plus-erlotinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab